John Lowe

Senior Director, Pathology

POSTDOC MENTOR

"Harnessing scientific inquiry for the development of new drugs is an exciting and important endeavor and is made especially satisfying by the scientifically rigorous environment at Genentech."

• 5
  years at Genentech
• 9
  publications (2010-12)
• 10
  awards & honors

I joined Genentech in 2008 as Senior Director of Pathology. The role of Senior Director of Pathology in Research at Genentech offered attractive opportunities to do research in an outstanding, disease-focused scientific environment, while also leading the growth and development of the scientific discovery and research support activities of the Pathology department. These efforts will help Genentech continue to make a major positive difference to the health and well being of a large number of patients afflicted with cancer, autoimmune syndromes, neurodegenerative diseases and other illnesses for which therapies are unsatisfactory or nonexistent.

An exceptional team of pathologists, scientific associates and administrative staff now in the department will collaborate with me in these efforts. Additional outstanding pathologists and staff will be recruited to assist us in developing the department. Our task will be made more straightforward by the environment here at Genentech, which is characterized by exceptionally bright, motivated and collaborative colleagues at every level; spectacular facilities, and workplace philosophies that are conducive to the highest levels of achievement.

• My Focus

  Each pathologist in my department maintains his or her own research program that typically aligns with the research programs supervised by scientists in Research Oncology, Immunology, Molecular Biology and Physiological Chemistry. These research projects include understanding basic mechanisms of angiogenesis - how these go awry in association with oncogenesis, and how such aberrancies provide therapeutic opportunities.

  Other projects include those that focus on developing an understanding of the basis for molecular heterogeneity in breast cancer and on discovering how faults in the mucosal immune system initiate and perpetuate the pathology of inflammatory bowel disease.

• Publications

  • Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans

    Pharmaceutical Research, 2012, ISSN: 0724-8741

    Xin, Yan; Bai, Shuang; Damico-Beyer, Lisa A.; Jin, Denise; Liang, Wei-Ching; Wu, Yan; Theil, Frank-Peter; Joshi, Amita; Lu, Yanmei; Lowe, John; Maia, Mauricio; Brachmann, Rainer K.; Xiang, Hong

     View on PubMed

  • Introduction for the Special Issue on Glycosylation and Immunity

    Seminars in Immunopathology, 2012, ISSN: 1863-2297

    Lowe, John;

     View on PubMed

  • Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.

    Journal of Pharmaceutical and Biomedical Analysis, 2011, ISSN: 0731-7085

    Finco, D.; Baltrukonis, D.; Clements, E.; Delaria, K.; Gunn, G.; Lowe, J.; Maia, M.; Wong, T.

     View on PubMed

  • A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum.

    Journal of Immunological Methods, 2010, ISSN: 1872-7905

    Zhihua, J.Q.; Ying, Y.; Fox, M.; Peng, K.; Lewin-Koh, S.-C.; Coleman, D.; Good, J.; Lowe, J.; Rahman, A.; Yang, J.; Jiang, J.; Quarmby, V.; Song, A.

  • O-Fucose Modulates Notch-Controlled Blood Lineage Commitment.

    American Journal of Pathology, 2010, ISSN: 0002-9440

    Yan, Q.; Yao, D.; Wei, L.; Huang, Y.; Myers, J.; Zhang, L.; Xin, W.; Shim, J.; Man, Y.; Petryniak, B.; Gerson, S.; Lowe, J.; Zhou, L.

  • A Therapeutic Anti-VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life.

    Cancer Research, 2010, ISSN: 1538-7445

    Yeung, Y.A.; Wu, X.; Reyes, A.E. 2nd.; Vernes, J.M.; Lien, S.; Lowe, J.; Maia, M.; Forrest, W.F.; Meng, Y.G.; Damico, L.A.; Ferrara, N.; Lowman, H.B.

  • Development of a novel homogenous electrochemiluminescence assay for quantitation of ranibizumab in human serum.

    Journal of Pharmaceutical & Biomedical Analysis, 2010, ISSN: 1873-264X

    Lowe, J.; Maia, M.; Wakshull, E.; Siguenza, P.; Liu, P.; Lakhani, S.; Rusit, J.; Elliott, R.; Quarmby, V.

  • Fucosyltransferase IV and VII-directed selectin ligand function determines long-term survival in experimental tuberculosis.

    Immunobiology, 2009, ISSN: 0171-2985

    Ehlers, S.; Schreiber, T.; Dunzendorfer, A.; Lowe, J.B.; Holscher, C.

  • Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo

    Experimental Eye Research, 2007, ISSN:

    Lowe, J.; Araujo, J.; Yang, J.; Reich, M.; Oldendorp, A.; Shiu, V.; Quarmby, V.; Lowman, H.; Lien, S.; Gaudreault, J.; Maia, M.

• Education
  • Washington University School of Medicine, Post-doctoral Fellowships – 1984
  • Washington University School of Medicine, Laboratory Medicine, Resident – 1983
  • University of Utah College of Medicine, M.D. – 1980
  • University of Wyoming, Mathematics, B.A. – 1976
• Awards & Honors
  • Henry Willson Payne Professorship at Case Western Reserve University School of Medicine – 2005
  • Elected Fellow, American Association for the Advancement of Science – 2002
  • Elected Member, American Association of Physicians – 1999
  • American Society of Clinical Pathologists Philip Levine Outstanding Research Award – 1997
  • Warner Lambert/Parke Davis Professorship in Medicine at the University of Michigan School of Medicin – 1994
  • Elected Member, American Society for Clinical Investigation – 1994
  • Howard and Martha Holley Symposium Research Prize in Rheumatology, American College of Rheumatology – 1993
  • Warner-Lambert/Parke-Davis Award in Experimental Pathology – 1992
  • American Cancer Society Postdoctoral Fellow – 1983
  • Phi Beta Kappa, University of Wyoming – 1975